Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ANI PharmaceuticalsANIP -5.35%80 Cash Ratio is 1.36 as of Mar. 2026, which is 86% above its 10-year median of 0.73. GuruFocus rates ANIP with a GF Score™ of 80/100 and a GF Value™ of $101.57 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 973 Drug Manufacturers companies, ANI Pharmaceuticals ranks better than 70.2% on this metric.
ANI Pharmaceuticals has a Cash Ratio of 1.36. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for ANI Pharmaceuticals's Cash Ratio or its related term are showing as below:
ANIP'
s Cash Ratio Range Over the Past 10 Years
Min: 0.1 Med: 0.73 Max: 1.76
Current: 1.36
During the past 13 years, ANI Pharmaceuticals's highest Cash Ratio was 1.76. The lowest was 0.10. And the median was 0.73.
ANIP's Cash Ratio is ranked better than 70.2% of 973
companies
in the Drug Manufacturers industry
Industry Median: 0.6
vs ANIP: 1.36
ANI Pharmaceuticals (NAS:ANIP) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
ANI Pharmaceuticals Cash Ratio Related Terms
ANI Pharmaceuticals Cash Ratio Historical Data
* Premium members only.
The historical data trend for ANI Pharmaceuticals's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, ANI Pharmaceuticals's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ANI Pharmaceuticals Cash Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ANI Pharmaceuticals's Cash Ratio distribution charts can be found below:
* The bar in red indicates where ANI Pharmaceuticals's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ANI Pharmaceuticals (ANIP) has a Cash Ratio of 1.36 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on ANI Pharmaceuticals and its competitors. This is 86% above median its historical median of 0.73. Over the past decade, ANI Pharmaceuticals' Cash Ratio has ranged from 0.10 to 1.76. According to the industry distribution chart, ANI Pharmaceuticals ranks #290 out of 973 companies in the Drug Manufacturers industry, placing it in the top 29.8%.
Is ANI Pharmaceuticals' Cash Ratio too high?
ANI Pharmaceuticals' current Cash Ratio of 1.36 is 86% above median its 10-year median of 0.73. Over the past 10 years, this metric has ranged from a low of 0.10 to a high of 1.76. The Drug Manufacturers industry median Cash Ratio is 0.60. ANI Pharmaceuticals' value of 1.36 is 126.7% above this industry median. Based on the distribution chart, ANI Pharmaceuticals ranks #290 out of 973 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, ANI Pharmaceuticals has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ANI Pharmaceuticals' Cash Ratio compare to TRLV and AMLX?
According to the Drug Manufacturers industry distribution chart, ANI Pharmaceuticals ranks #290 out of 973 companies for Cash Ratio. This puts ANI Pharmaceuticals in the upper half of its industry. The industry median Cash Ratio is 0.60. ANI Pharmaceuticals' value of 1.36 is 126.7% above this benchmark. Historically, ANI Pharmaceuticals' own Cash Ratio has ranged from 0.10 to 1.76 over the past decade. While the company's 10-year median is 0.73 vs. the industry median of 0.60, ANI Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Drug Manufacturers company?
The median Cash Ratio among Drug Manufacturers companies is 0.60, based on 973 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ANI Pharmaceuticals's current Cash Ratio of 1.36 is 126.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on ANI Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Cash Ratio is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ANI Pharmaceuticals's current Cash Ratio is 1.36, which is 86% above median its own 10-year median of 0.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ANI Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, ANI Pharmaceuticals (ANIP) is currently considered Modestly Undervalued. The stock's GF Value™ is $101.57, compared to a current price of $78.45 — trading 22.8% below its estimated fair value. The current Cash Ratio is 1.36, which is 86% above median its 10-year median of 0.73 and 126.7% above the Drug Manufacturers industry median of 0.60. ANI Pharmaceuticals' overall GF Score™ is 80/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For ANI Pharmaceuticals (ANIP), the current Cash Ratio is 1.36 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ANI Pharmaceuticals (ANIP) Overvalued in 2026?
Based on GuruFocus' analysis, ANI Pharmaceuticals stock appears to be undervalued.
The current stock price of $78.45 is trading 22.8% below its estimated GF Value™ of $101.57.
GuruFocus considers ANI Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for ANIP:
Cash Ratio: 1.36 (86% above median its 10-year median of 0.73)
GF Value™: $101.57 vs. price of $78.45 (22.8% below fair value)
Industry Position: 126.7% above the Drug Manufacturers median (#290 of 973)
No single metric tells the full story. See the ANIP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.
80GF Score
Get the complete analysis for ANIP
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ANIP has been successfully added to your 
